Literature DB >> 12239606

Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients.

L Bai1, J Koopmann, C Fiola, P Fournier, V Schirrmacher.   

Abstract

We demonstrated before that primary operated breast cancer patients contain in their bone marrow (BM) cancer reactive memory T cells (MTC) which have to be re-activated to become tumor infiltrating effector cells. The aim of this study was to optimize an ex vivo stimulation protocol for MTC based on autologous dendritic cells (DC). As source of tumor antigens we used lysates from unmodified tumor cells or from tumor cells infected with Newcastle Disease Virus (NDV) which contain IFN-alpha inducing viral dsRNA as one danger signal. DC from breast cancer patients were pulsed with lysates from the MCF-7 breast cancer line (Tu-L) or from NDV infected MCF-7 cells (TuN-L, viral oncolysates) and compared for stimulatory capacity in an ELISPOT response of autologous BM derived MTC. To analyze potential further danger signals derived from NDV infection, we employed MALDI mass spectrometry, Western blots, FACS cytometry and ELISA tests. DC pulsed with viral oncolysates showed increased expression of co-stimulatory molecules in comparison to Tu-L pulsed DC and induced significantly higher ELISPOT MTC responses. Supernatants from co-cultures of MTC and TuN-L pulsed DC contained increased titers of IFN-alpha and IL-15. NDV infection of tumor cells resulted in a number of differences in protein expression including a heat-shock protein (HSP27) which became phosphorylated. The results suggest that a DC preparation pulsed with viral oncolysate includes danger signals (e.g. dsRNA, cytokines, HSP molecules) and is superior for MTC stimulation to a DC preparation pulsed with lysate from non-infected tumor cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239606     DOI: 10.3892/ijo.21.4.685

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  19 in total

1.  Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.

Authors:  B Montico; C Lapenta; M Ravo; D Martorelli; E Muraro; B Zeng; E Comaro; M Spada; S Donati; S M Santini; R Tarallo; G Giurato; F Rizzo; A Weisz; F Belardelli; R Dolcetti; J Dal Col
Journal:  Oncoimmunology       Date:  2017-07-31       Impact factor: 8.110

2.  Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.

Authors:  Philipp Beckhove; Markus Feuerer; Mathias Dolenc; Florian Schuetz; Carmen Choi; Nora Sommerfeldt; Jochen Schwendemann; Katrin Ehlert; Peter Altevogt; Gunther Bastert; Volker Schirrmacher; Viktor Umansky
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

3.  Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

Authors:  Robin J Prestwich; Fiona Errington; Elizabeth J Ilett; Ruth S M Morgan; Karen J Scott; Timothy Kottke; Jill Thompson; Ewan E Morrison; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

Review 4.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

5.  Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis.

Authors:  Lianhua Bai; Donald P Lennon; Valerie Eaton; Kari Maier; Arnold I Caplan; Stephen D Miller; Robert H Miller
Journal:  Glia       Date:  2009-08-15       Impact factor: 7.452

Review 6.  Safety and clinical usage of newcastle disease virus in cancer therapy.

Authors:  Han Yuen Lam; Swee Keong Yeap; Mehdi R Pirozyan; Abdul Rahman Omar; Khatijah Yusoff; Abd Aziz Suraini; Noorjahan Banu Alitheen
Journal:  J Biomed Biotechnol       Date:  2011-10-26

Review 7.  Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.

Authors:  Barbara Montico; Annunziata Nigro; Vincenzo Casolaro; Jessica Dal Col
Journal:  Int J Mol Sci       Date:  2018-02-16       Impact factor: 5.923

8.  Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.

Authors:  Philippe Fournier; Volker Schirrmacher
Journal:  Biology (Basel)       Date:  2013-07-02

Review 9.  Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.

Authors:  Volker Schirrmacher; Philippe Fournier
Journal:  Front Oncol       Date:  2014-09-11       Impact factor: 6.244

Review 10.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.